Lemaitre Vascular (LMAT) Total Non-Current Liabilities (2010 - 2026)
Lemaitre Vascular's (LMAT) quarterly Total Non-Current Liabilities came in at $218.7 million in Q2 2026, up 2.23% year-over-year from $214.0 million in Q2 2025, and down 1.28% quarter-over-quarter from $221.6 million in Q1 2026.
Analysis
Lemaitre Vascular (LMAT) Total Non-Current Liabilities (2010 - 2026) Analysis & Trends
Lemaitre Vascular (LMAT) has reported Total Non-Current Liabilities for 17 consecutive years, with $218.7 million the latest figure, recorded in Q2 2026.
- On a quarterly basis, Total Non-Current Liabilities rose 2.23% year-over-year to $218.7 million in Q2 2026; TTM through Jun 2026 was $218.7 million, a 2.23% increase from a year earlier, with the FY2025 full-year figure at $220.7 million, up 3.28% from the prior year.
- Total Non-Current Liabilities was $218.7 million for Q2 2026 at Lemaitre Vascular, down from $221.6 million in the prior quarter.
- Over five years, Total Non-Current Liabilities peaked at $221.6 million in Q1 2026 and troughed at $32.0 million in Q1 2022.
- A 5-year average of $109.0 million and a median of $44.2 million in 2024 frame the typical range for Total Non-Current Liabilities.
- Across the five-year window, Total Non-Current Liabilities sank 50.91% in 2022 and jumped 417.24% in 2025, its largest moves.
- Over 5 years, Total Non-Current Liabilities stood at $40.1 million in 2022, then increased by 16.21% to $46.6 million in 2023, then soared by 358.48% to $213.7 million in 2024, then gained by 3.28% to $220.7 million in 2025, then retreated by 0.89% to $218.7 million in 2026.
- The last three Total Non-Current Liabilities figures came in at $218.7 million (Q2 2026), $221.6 million (Q1 2026), and $220.7 million (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 179.79 Bn | 174.18 Bn | 7.27 Bn | - |
| 2 | Intuitive Surgical | 127.69 Bn | 122.47 Bn | 1.96 Bn | 1.92 Bn |
| 3 | Medtronic | 117.23 Bn | 108.41 Bn | 6.34 Bn | 40.46 Bn |
| 4 | Stryker | 103.55 Bn | 100.07 Bn | 4.50 Bn | 21.28 Bn |
| 5 | Boston Scientific | 63.24 Bn | 62.70 Bn | 3.85 Bn | 17.56 Bn |
| 6 | Edwards Lifesciences | 49.97 Bn | 45.72 Bn | 1.35 Bn | 2.57 Bn |
| 7 | Alcon | 32.83 Bn | 31.37 Bn | 1.68 Bn | 6.34 Bn |
| 8 | Dexcom | 32.30 Bn | 30.35 Bn | 830.00 Mn | 3.68 Bn |
| 9 | Steris | 20.73 Bn | 20.25 Bn | 684.20 Mn | 3.44 Bn |
| 10 | Lemaitre Vascular | 1.80 Bn | 1.43 Bn | 50.76 Mn | 218.75 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 218.75 Mn |
| Mar 31, 2026 | 221.59 Mn |
| Dec 31, 2025 | 220.71 Mn |
| Sep 30, 2025 | 218.21 Mn |
| Jun 30, 2025 | 213.97 Mn |
| Mar 31, 2025 | 207.56 Mn |
| Dec 31, 2024 | 213.70 Mn |
| Sep 30, 2024 | 45.06 Mn |
| Jun 30, 2024 | 41.37 Mn |
| Mar 31, 2024 | 43.28 Mn |
| Dec 31, 2023 | 46.61 Mn |
| Sep 30, 2023 | 43.23 Mn |
| Jun 30, 2023 | 40.38 Mn |
| Mar 31, 2023 | 38.42 Mn |
| Dec 31, 2022 | 40.11 Mn |
| Sep 30, 2022 | 38.40 Mn |
| Jun 30, 2022 | 38.89 Mn |
| Mar 31, 2022 | 32.04 Mn |
| Dec 31, 2021 | 35.95 Mn |
| Sep 30, 2021 | 36.83 Mn |